Sentinel lymph node mapping for staging breast cancer: preliminary results of a prospective study.

S. Rehman, A. Sardi, E. Spiegler, J. Colandrea, D. Frishberg

Research output: Contribution to journalArticle

Abstract

Axillary lymph node dissection is the gold standard for staging breast cancer, but it is associated with significant morbidity and complications. Sentinel lymph node mapping technique has demonstrated a successful detection of the node or nodes more likely to have metastasis. Two techniques are being used to detect sentinel lymph node-intraoperative use of gamma detecting probe after injection of radio tracer preoperatively and the injection of blue dye and lymphatic mapping intraoperatively. We used both techniques. Twenty-four patients underwent sentinel lymph node mapping. Blue dye and gamma detecting probe identified sentinel lymph nodes in 78% and 77% of patients, respectively. Overall, 23 of 24 patients had a sentinel lymph node identified (96%). Ten patients had metastatic disease in the axilla. Out of these ten patients the only positive node/nodes were the sentinel lymph node in six patients. The other four patients had positive non-sentinel lymph node along with positive sentinel lymph node. All of the patients who had metastatic disease in the axilla were detected by the sentinel lymph node mapping technique. Therefore, no patient had positive non-sentinel lymph node if the sentinel lymph node was negative. This technique was 100% predictive of the axillary status. Sentinel lymph node mapping technique will change the management of breast cancer and will allow two-thirds of the patients with breast cancer to be managed without axillary lymph node dissection with a resulting reduction in morbidity and cost.

Original languageEnglish (US)
Pages (from-to)105-110
Number of pages6
JournalMaryland medical journal (Baltimore, Md. : 1985)
Volume48
Issue number3
StatePublished - 1999

Fingerprint

Prospective Studies
Breast Neoplasms
Axilla
Lymph Node Excision
Coloring Agents
Lymph Nodes
Sentinel Lymph Node
Morbidity
Injections
Radio
Neoplasm Metastasis
Costs and Cost Analysis

Cite this

Sentinel lymph node mapping for staging breast cancer : preliminary results of a prospective study. / Rehman, S.; Sardi, A.; Spiegler, E.; Colandrea, J.; Frishberg, D.

In: Maryland medical journal (Baltimore, Md. : 1985), Vol. 48, No. 3, 1999, p. 105-110.

Research output: Contribution to journalArticle

Rehman, S, Sardi, A, Spiegler, E, Colandrea, J & Frishberg, D 1999, 'Sentinel lymph node mapping for staging breast cancer: preliminary results of a prospective study.', Maryland medical journal (Baltimore, Md. : 1985), vol. 48, no. 3, pp. 105-110.
Rehman, S. ; Sardi, A. ; Spiegler, E. ; Colandrea, J. ; Frishberg, D. / Sentinel lymph node mapping for staging breast cancer : preliminary results of a prospective study. In: Maryland medical journal (Baltimore, Md. : 1985). 1999 ; Vol. 48, No. 3. pp. 105-110.
@article{c2d9a58c45dd4530a8168bc7e65d92eb,
title = "Sentinel lymph node mapping for staging breast cancer: preliminary results of a prospective study.",
abstract = "Axillary lymph node dissection is the gold standard for staging breast cancer, but it is associated with significant morbidity and complications. Sentinel lymph node mapping technique has demonstrated a successful detection of the node or nodes more likely to have metastasis. Two techniques are being used to detect sentinel lymph node-intraoperative use of gamma detecting probe after injection of radio tracer preoperatively and the injection of blue dye and lymphatic mapping intraoperatively. We used both techniques. Twenty-four patients underwent sentinel lymph node mapping. Blue dye and gamma detecting probe identified sentinel lymph nodes in 78{\%} and 77{\%} of patients, respectively. Overall, 23 of 24 patients had a sentinel lymph node identified (96{\%}). Ten patients had metastatic disease in the axilla. Out of these ten patients the only positive node/nodes were the sentinel lymph node in six patients. The other four patients had positive non-sentinel lymph node along with positive sentinel lymph node. All of the patients who had metastatic disease in the axilla were detected by the sentinel lymph node mapping technique. Therefore, no patient had positive non-sentinel lymph node if the sentinel lymph node was negative. This technique was 100{\%} predictive of the axillary status. Sentinel lymph node mapping technique will change the management of breast cancer and will allow two-thirds of the patients with breast cancer to be managed without axillary lymph node dissection with a resulting reduction in morbidity and cost.",
author = "S. Rehman and A. Sardi and E. Spiegler and J. Colandrea and D. Frishberg",
year = "1999",
language = "English (US)",
volume = "48",
pages = "105--110",
journal = "Maryland Medical Journal",
issn = "1538-2656",
publisher = "Medical and Chirugical Faculty of Maryland",
number = "3",

}

TY - JOUR

T1 - Sentinel lymph node mapping for staging breast cancer

T2 - preliminary results of a prospective study.

AU - Rehman, S.

AU - Sardi, A.

AU - Spiegler, E.

AU - Colandrea, J.

AU - Frishberg, D.

PY - 1999

Y1 - 1999

N2 - Axillary lymph node dissection is the gold standard for staging breast cancer, but it is associated with significant morbidity and complications. Sentinel lymph node mapping technique has demonstrated a successful detection of the node or nodes more likely to have metastasis. Two techniques are being used to detect sentinel lymph node-intraoperative use of gamma detecting probe after injection of radio tracer preoperatively and the injection of blue dye and lymphatic mapping intraoperatively. We used both techniques. Twenty-four patients underwent sentinel lymph node mapping. Blue dye and gamma detecting probe identified sentinel lymph nodes in 78% and 77% of patients, respectively. Overall, 23 of 24 patients had a sentinel lymph node identified (96%). Ten patients had metastatic disease in the axilla. Out of these ten patients the only positive node/nodes were the sentinel lymph node in six patients. The other four patients had positive non-sentinel lymph node along with positive sentinel lymph node. All of the patients who had metastatic disease in the axilla were detected by the sentinel lymph node mapping technique. Therefore, no patient had positive non-sentinel lymph node if the sentinel lymph node was negative. This technique was 100% predictive of the axillary status. Sentinel lymph node mapping technique will change the management of breast cancer and will allow two-thirds of the patients with breast cancer to be managed without axillary lymph node dissection with a resulting reduction in morbidity and cost.

AB - Axillary lymph node dissection is the gold standard for staging breast cancer, but it is associated with significant morbidity and complications. Sentinel lymph node mapping technique has demonstrated a successful detection of the node or nodes more likely to have metastasis. Two techniques are being used to detect sentinel lymph node-intraoperative use of gamma detecting probe after injection of radio tracer preoperatively and the injection of blue dye and lymphatic mapping intraoperatively. We used both techniques. Twenty-four patients underwent sentinel lymph node mapping. Blue dye and gamma detecting probe identified sentinel lymph nodes in 78% and 77% of patients, respectively. Overall, 23 of 24 patients had a sentinel lymph node identified (96%). Ten patients had metastatic disease in the axilla. Out of these ten patients the only positive node/nodes were the sentinel lymph node in six patients. The other four patients had positive non-sentinel lymph node along with positive sentinel lymph node. All of the patients who had metastatic disease in the axilla were detected by the sentinel lymph node mapping technique. Therefore, no patient had positive non-sentinel lymph node if the sentinel lymph node was negative. This technique was 100% predictive of the axillary status. Sentinel lymph node mapping technique will change the management of breast cancer and will allow two-thirds of the patients with breast cancer to be managed without axillary lymph node dissection with a resulting reduction in morbidity and cost.

UR - http://www.scopus.com/inward/record.url?scp=0033124459&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033124459&partnerID=8YFLogxK

M3 - Article

C2 - 10394225

AN - SCOPUS:0033124459

VL - 48

SP - 105

EP - 110

JO - Maryland Medical Journal

JF - Maryland Medical Journal

SN - 1538-2656

IS - 3

ER -